News Releases

Below are the latest News Releases for Clearmind Medicine Inc.

13

08

2026

Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
Read More
11

08

2026

Clearmind Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention ...
Read More
6

August

2026

Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study
Read More
3

August

2026

Clearmind Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems...
Read More
30

July

2026

Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability in Part A of its Clinical Trial
Read More
20

July

2026

Clearmind Expands Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion...
Read More
17

July

2026

Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
Read More
16

July

2026

Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
Read More
13

July

2026

Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
Read More
10

July

2026

Clearmind Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery
Read More
7

July

2026

Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration for MEAI
Read More
29

June

2026

Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
Read More
22

June

2026

Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
Read More
18

June

2026

Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators
Read More
16

June

2026

Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
Read More